Polarean Imaging PLC chief business officer Alex Dusek talked with Proactive's Stephen Gunnion about the company’s latest expansion into pharmaceutical-sponsored trials. This new initiative involves a multinational trial utilising Polarean’s Xenon MRI technology to assist drug development for lung diseases.
Dusek explained that traditional lung function tests, such as spirometry, are crude and highly variable, making trials costly and time-consuming. Xenon MRI offers a more sensitive measurement, reducing variability and allowing drug companies to conduct trials with significantly fewer patients. "If you're designing a trial, let's say it's 25 to 50 patients with Xenon, that would take you 250 to 500 patients with the more traditional measures," he noted.
Polarean is providing pharmaceutical companies with imaging biomarkers and harmonised data analysis, streamlining drug development. The company is also establishing a network of clinical sites equipped with Xenon MRI, creating an ecosystem that benefits sponsors, trial sites, and Polarean itself.
Dusek highlighted Polarean’s partnership with VIDA Diagnostics, a well-known name in lung drug development, to further enhance the impact of this initiative.
For more insights into Polarean Imaging’s latest developments, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for future updates.
#PolareanImaging #XenonMRI #LungDisease #DrugDevelopment #ClinicalTrials #PharmaResearch #MedicalImaging #Biotech #HealthcareInnovation #Investing
